R (on the application of Ullah) v Special Adjudicator [2004] UKHL 26, House of Lords

Autor: Thomas E. Webb

Publikováno v: Essential Cases: Public Law

Essential Cases: Public Law provides a bridge between course textbooks and key case judgments. This case document summarizes the facts and decision in R (on the application of Ullah) v Special Adjudicator [2004] UKHL 26, House of Lords. The substanti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133e455d28b71b1c46dfef0393ff0050
https://doi.org/10.1093/he/9780191897689.003.0058

Regina (Ullah) v. Special Adjudicator;

Autor: Karen Lee, Christopher Greenwood, Elihu Lauterpacht, A. G. Oppenheimer

Publikováno v: International Law Reports

577Aliens — Entry — Asylum — Asylum-seeker failing to establish refugee status — Other grounds for claiming asylum — Claim that asylum-seeker’s rights to practise, teach and preach religion would be violated — Whether sufficient ground

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7c2b99f61cba80f5a27272091f8e47a
https://doi.org/10.1017/cbo9781316152638.014

Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma.

Autor: Perry MWD; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Björhall K; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Bold P; DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Brűlls M; Early Product Development & Manufacturing, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Börjesson U; Computational Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Carlsson J; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Chang HA; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Chen Y; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Eriksson A; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Fihn BM; DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Fransson R; Advanced Drug Delivery, Pharmaceutical Sciences R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Fredlund L; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Ge H; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Huang H; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Karabelas K; Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Lamm Bergström E; DMPK, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Lever S; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Lindmark H; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Mogemark M; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Nikitidis A; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Palmgren AP; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Pemberton N; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Petersen J; Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Rodrigo Blomqvist M; Bioscience Cough and In Vivo, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Smith RW; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Thomas MJ; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Ullah V; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Tyrchan C; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Wennberg T; Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Westin Eriksson A; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden., Yang W; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Zhao S; Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China., Öster L; Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Jun 24; Vol. 64 (12), pp. 8053-8075. Date of Electronic Publication: 2021 Jun 03.

Strong Decisions and Stare Decisis in co-ordinate Courts.

Autor: Graham, Lewis¹ Lewis.graham@wadham.ox.ac.uk

Publikováno v: King's Law Journal. Sep2024, Vol. 35 Issue 2, p224-251. 28p.

Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1 S ,2 S )-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma.

Autor: Munck Af Rosenschöld M, Johannesson P, Nikitidis A, Tyrchan C, Chang HF, Rönn R; Orexo AB , Virdings allé 32A , SE-75450 Uppsala , Sweden., Chapman D, Ullah V, Nikitidis G, Glader P, Käck H, Bonn B, Wågberg F, Björkstrand E; Orexo AB , Virdings allé 32A , SE-75450 Uppsala , Sweden., Andersson U, Swedin L, Rohman M, Andreasson T, Bergström EL, Jiang F, Zhou XH, Lundqvist AJ, Malmberg A, Ek M, Gordon E, Pettersen A, Ripa L, Davis AM

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2019 Sep 12; Vol. 62 (17), pp. 7769-7787. Date of Electronic Publication: 2019 Aug 30.